UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

January 07, 2021

Sara A. Hurvitz, MD, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.

November 24, 2020

Paul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.

November 02, 2020

Ritu Salani, MD, MBA, discusses therapeutic advances in endometrial cancer.

November 02, 2020

Gottfried E. Konecny, MD, discusses potential strategies to overcome PARP resistance, future combinations with PARP inhibitors, and other unmet needs in ovarian cancer.

October 31, 2020

Ritu Salani, MD, MBA, discusses updates to PARP inhibition and FRα-targeting agents in ovarian cancer, the role of bevacizumab across all lines of ovarian cancer therapy, and immunotherapy highlights in cervical and endometrial cancer.

October 30, 2020

Mae Zakhour, MD, discusses the rise of PARP inhibitors as frontline maintenance therapy in advanced ovarian cancer and the key data that supported these regulatory decisions.

October 26, 2020

Paul C. Boutros, PhD, MBA, discusses processes that predict disease lethality in men with prostate cancer.

August 27, 2020

Edward B. Garon, MD, discusses remaining questions with fam-trastuzumab deruxtecan-nxki in the field of lung cancer.

August 21, 2020

Edward B. Garon, MD, discusses unique challenges of the coronavirus disease 2019 in lung cancer.

August 21, 2020

Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.

August 10, 2020

Grace Cherry, RN, ​MSN, NP, discusses ​recent advances in melanoma. 

June 04, 2020

Researchers at the UCLA Jonsson Comprehensive Cancer Center analyze gene-expression patterns in the most aggressive prostate cancer grade group—known as Gleason grade group 5—and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences.

May 28, 2020

In our exclusive interview, Dr. Karlan shares the rewarding moments and challenges she has encountered in the cancer space as a female oncologist, pivotal research she has been spearheaded that has lasting impacts on the field, and other developments in gynecologic cancers that are poised to change the landscape forever.

May 14, 2020

Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.

May 14, 2020

Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.

May 14, 2020

For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.

May 13, 2020

For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.

April 25, 2020

Although fewer patients are undergoing cytoreductive nephrectomy as systemic treatments for renal cell carcinoma improve, the modality still has a vital role to play in the treatment paradigm—even in the modern age of immune checkpoint inhibitors.

April 04, 2020

Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.

March 25, 2020

Jonathan W. Goldman, MD, health sciences clinical instructor, Department of Medicine, and Hematology/Oncology member, Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program, UCLA, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer (NSCLC).